background: Polycystic ovary syndrome (PCOS) tends to run in families and excess intrauterine androgen exposure has been suggested as one possible cause of PCOS. We wanted to study the relationship between maternal and offspring sex hormone levels and the possible effects of metformin treatment in PCOS pregnancies.
Introduction
Polycystic ovary syndrome (PCOS) is a heterogenic disorder characterized by polycystic ovaries, oligoamenorrhea and hyperandrogenism (Ehrmann, 2005) . Some studies show that PCOS run in families and an autosomal dominant inheritance has been suggested (Amato and Simpson, 2004) . However, attempts to identify genes involved have, until now, been without success. This indicates that other mechanisms promoting familial clustering may be involved.
PCOS women have elevated androgen levels also when pregnant (Sir-Petermann et al., 2002) . Recently, intrauterine androgen exposure has been proposed as one possible pathogenic mechanism for the development of PCOS (Xita and Tsatsoulis, 2006; Homburg, 2009) . Whether elevated maternal androgen levels are reflected in fetal blood is not known.
Metformin has been proposed for the prevention of pregnancy complications and adverse pregnancy outcome in PCOS women. In a randomized, placebo controlled study of pregnant PCOS women (Vanky et al., 2004) , we found that, contrary to our hypothesis, metformin did not affect maternal androgen levels, but the number of over-all pregnancy complications was reduced. We also found that metformin was present in the fetal blood in therapeutic concentrations (Vanky et al., 2005) . This made us wonder whether metformin treatment of pregnant PCOS women affected hormone levels in the newborn.
To investigate the relationship between maternal and offspring hormone levels at birth and the potential effect of metformin on maternal and newborn hormone levels, we used stored serum from our previously published study (Vanky et al., 2004) .
Materials and Methods
From October 2000 to March 2003, 40 pregnant women with PCOS were included in a prospective, randomized, placebo controlled study at St. Olav's Hospital, Trondheim University Hospital. The PCOS diagnosis was based on the presence of polycystic ovaries (nine or more subcapsular follicles with a diameter of 3 -8 mm) verified by transvaginal ultrasonography. Furthermore, at least one of the following five criteria had to be present: testosterone . 2.5 nmol/l, sex hormone-binding globulin (SHBG) , 30 nmol/l, fasting insulin C-peptide . 1.0 nmol/l, oligomenorrhea (length of menstrual cycle .35 days or ,10 periods per year) or hirsutism, judged clinically as male pattern growth of body hair. This was before the statement of the Rotterdam criteria. In retrospect, all participants met the 'Revised 2003 consensus' on diagnostic criteria for PCOS, implying that at least two of the three following criteria were met: polycystic ovaries, hyperandrogenism (clinical and/or biochemical) and oligo-or anovulation (Vanky et al., 2004) .
The inclusion criteria for the study were: (i) diagnosis of PCOS before the present pregnancy, (ii) age 18 -40 years, (iii) gestational age between 5 and 12 weeks, and a singleton viable fetus diagnosed by ultrasonography.
The exclusion criteria were known liver disease, s-creatinine . 130 mmol/l, known alcohol abuse, previously known diabetes mellitus, fasting plasma glucose . 5.6 mmol/l, treatment with oral glucocorticoids or use of drugs known to interfere with metformin.
There were 18 women randomized to receive metformin and 22 to receive placebo. Randomization was performed in blocks of 10 and women were stratified according to whether or not they used metformin at conception. Two women, one in each group, withdrew for personal reasons within 2 weeks of inclusion. For another two women, serum samples from delivery were not available. Accordingly, for the present study we had blood samples from 16 metformin-treated and 20 placebotreated PCOS women.
The participants received written and verbal diet and lifestyle counselling at inclusion. They were randomized to treatment with metformin 425 mg (metformin hydrochloride, Metformin w ; Weifa AS, Oslo, Norway) or identical placebo capsules. The participants were instructed to take two capsules once daily during the first week then two capsules twice daily until delivery. In addition, they all received 1 mg folic acid and a multivitamin tablet daily.
Venous blood samples from the mother and venous and arterial umbilical cord blood were collected (separately) within 1 h of birth.
We analysed dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), androstenedione, dihydrotestosterone (DHT), SHBG, testosterone, androstanediol glucuronide (5a-androstane-3a, 17b-diol-glucoronide, ADG), estrone, estradiol and estriol in both maternal serum and umbilical arterial and venous serum. ADG is a metabolite of DHEA, DHEAS, androstenedione, testosterone and DHT. DHT is the major contributor to ADG. These two substances were included in the analyses to make the evaluation of the possible effect of metformin on androgen levels and metabolism more complete.
Written informed consent was obtained from each patient before inclusion and the declaration of Helsinki was followed throughout the study. The Committee for Medical Research Ethics of Health Region IV, Norway, and The Norwegian Medicines Agency approved the study. The study was not registered as it was performed before registration became mandatory.
DHEA, DHEAS, DHT, SHBG, ADG, estrone, estradiol, estriol were analysed by the ELISA technique with the reagents and calibrators supplied by the manufacturer (DRG Instruments GmbH, Marburg/Lahn, Germany). For serum testosterone and androstenedione analyses, we used organic solvent extraction (dichloromethane for testosterone and ethyl ether for androstenedione) prior to quantification. For quantification, we used the ELISA technique for testosterone (DRG Instruments GmbH, Marburg/ Lahn, Germany) and Coat-A-Count RIA kits (Diagnostic Products Corporation, Los Angeles, CA, USA) for androstenedione. The inter-and intra-assay coefficients of variation were for DHEA 6.0 and 1.0%, for DHEAS 6.6 and 4.0%, for androstenedione 5.3 and 2.8%, for testosterone 11.9 and 9.1%, for DHT 3.1 and 0.6%, for SHBG 12.0 and 2.0%, for ADG 5.1 and 1.7%, for estrone 4.9 and 10.2%, for estradiol 5.6 and 2.4% and for estriol 4.9 and 0.8%, accordingly.
All statistical procedures were performed using the SPSS version 15.0.1 for Windows (SPSS Inc., USA). The differences between the study groups were compared with two-tailed Mann -Whitney U-test for independent samples. Associations were investigated with univariable and multivariable linear regression analyses and adjusted for possible confounding factors. Values are reported as means + SD or as means and 95% confidence intervals (CI). P-values ,0.05 were considered significant. No adjustments for multiple comparisons were performed.
Results

Metformin versus placebo
SHBG was higher in the umbilical vein in newborns exposed to metformin in utero compared with those exposed to placebo (29 + 11 versus 19 + 11 nmol/l; P ¼ 0.005). Levels of DHEA, DHEAS, androstenedione, testosterone, DHT, ADG, estrone, estradione and estriol were similar in maternal blood, umbilical artery and umbilical vein in the metformin and placebo groups (Table I) .
Maternal hormone levels according to fetal gender
Mothers giving birth to boys, had higher levels of estrone (17 + 8 versus 12 + 8 nmol/l; P ¼ 0.028) and estradiol (34 + 16 versus 25 + 15 nmol/l; P ¼ 0.042), compared with those giving birth to girls (Table II) .
Newborn hormone levels according to gender
Compared with girls, boys had higher levels of testosterone in the umbilical artery (4.7 + 2.1 versus 3.2 + 1.0 nmol/l; P ¼ 0.025) and umbilical vein (4.2 + 1.6 versus 2.9 + 0.9 nmol/l; P ¼ 0.012), and higher ADG levels in the umbilical artery (30 + 11 versus 21 + 10 nmol/l; P ¼ 0.009) and umbilical vein (31 + 13 versus 19 + 9 nmol/l; P ¼ 0.002; Table II ). Estradiol was higher in the umbilical artery of boys compared with girls (55 + 37 versus 28 + 25 nmol/l; P ¼ 0.019).
Maternal versus fetal hormone levels
In both univariable and multivariable linear regression analyses, maternal levels of androstenedione, DHT and estradiol correlated with newborn levels in both the umbilical artery (P 0.016) and vein (P 0.004) (Table III) . In the multivariable analyses, adjusting for maternal age, BMI, parity and fetal gender, maternal levels of ADG and estriol were also associated with fetal levels in the umbilical artery (P 0.043) and maternal testosterone levels were associated with fetal umbilical vein levels (P ¼ 0.023) (Table III) .
Discussion
This is the first study to investigate a possible effect of metformin on maternal and newborn hormone levels at birth, in PCOS women. We found no effect of metformin on maternal hormone levels at birth. This is in accordance with our previous results where no effect of metformin was observed on maternal hormone levels or body weight from the first trimester and through to gestational Weeks 19, 32 and 36 (Vanky et al., 2004) .
The main finding of this study is that metformin seems to increase fetal SHBG levels. We have previously reported that metformin passes through the placenta and it is present in the fetal circulation in therapeutic concentrations (Vanky et al., 2005) . Metformin exerts part of its effect by reducing insulin resistance and thereby reducing circulating insulin levels (Mathur et al., 2008) . One effect of insulin is to inhibit the hepatic SHBG synthesis (Katz et al., 1993) . An important and well established effect of metformin in non-pregnant PCOS women is to increase SHBG levels (Barba et al., 2009) . In a random sample of newborns, umbilical venous SHBG levels were inversely associated with insulin and C peptide levels at birth both in males and females (Simmons, 1995) . Accordingly, we hypothesize that metformin may exert the same effect on insulin resistance and circulating insulin levels in the fetus, as reflected in higher SHBG levels at births. This would indicate that newborns of PCOS mothers are less insulin resistant if exposed to metformin in utero. An intriguing aspect of our observation is whether a possible intrauterine insulin sensitising effect of metformin, will be reflected later in life. Hence, we intend to follow-up these children at 6 -8 years of age to see if intrauterine metformin exposure has any long-term effect on their metabolism.
The observation that metformin has no effect on maternal SHBG levels might indicate that metformin in the mother, contrary to the fetus, does not affect markers of insulin resistance. During pregnancy, SHBG levels are increased by a factor of 10, probably secondary to the extreme elevation of estrogens in the maternal circulation, which stimulates hepatic SHBG synthesis. This estrogen effect possibly overrides the minor SHBG elevation induced by metformin that is secondary to reduced insulin levels.
Given the metformin effect on fetal SHBG levels, other markers of insulin resistance and glucose homeostasis could have been analysed. However, women in labour are not fasting and are often offered 'high energy drinks'. A shortage of serum means that further data on possible effects of metformin on fetal insulin resistance will have to wait until future studies.
In studies performing separate analyses of arterial and venous umbilical cord blood, elevated androgen levels have been found in male fetuses (Herruzo et al., 1993 , Simmons et al., 1994 had elevated testosterone and ADG levels although DHT was equal between the genders. This may be important as DHT is a more potent androgen than testosterone. DHT and ADG levels have rarely been investigated in umbilical cord blood previously (Dawood and Saxena, 1977) . Another interesting observation is that DHT in fetal serum is increased more than 2-fold compared with maternal levels. This is in contrast to a previous study of normal pregnancies (Dawood and Saxena, 1977) . We also investigated the possible correlation between maternal and newborn hormone levels, as androgens have been reported to be elevated in PCOS pregnancies compared with non-PCOS pregnancies (Sir-Petermann et al., 2002) Recently, the hypothesis that intrauterine androgen exposure is an important cause of PCOS, has been discussed (Xita and Tsatsoulis, 2006; Homburg, 2009 ). This hypothesis, together with the observation that PCOS is often clustered in families without an identified genetic cause (Amato and Simpson, 2004) , opens the possibility that PCOS runs in families due to increased fetal exposure to androgens. Our finding of a correlation between maternal and fetal androgen and estrogen levels support this theory that PCOS, at least in part, may be 'inherited' through an altered intrauterine endocrine milieu. However, the finding that maternal and offspring hormone levels correlate at birth does not necessarily implicate an association through the whole pregnancy. It also remains to be explore whether androgen levels are elevated at birth in female offspring of PCOS mothers compared with female offspring of non-PCOS mothers.
The strengths of the present study are that this was an analysis from a randomized controlled trial, conducted on a well defined population of pregnant PCOS women who were followed prospectively through pregnancy. The arterial and venous umbilical serum was collected separately. An obvious limitation is the relatively small number of participants which limits the variables that can be included in the multivariable regression analyses.
In conclusion, intrauterine metformin exposure seems to result in elevated SHBG levels in newborns. Metformin exposure throughout pregnancy exerts no major effects on maternal or newborn androgens or estrogens at birth. In boys compared with girls, both androgens and estrogens are elevated. We also found a correlation between maternal and newborn levels of androgens and estrogens at birth. Our observations support a possible role for intrauterine female androgen exposure in the offspring of PCOS women. Due to the limited study size, our results should be confirmed in future studies. 
